Wessels M R, Paoletti L C, Pinel J, Kasper D L
Division of Infectious Diseases, Beth Israel Hospital, Boston, Massachusetts.
J Infect Dis. 1995 Apr;171(4):879-84. doi: 10.1093/infdis/171.4.879.
The recent recognition of type V strains as a frequent cause of group B streptococcal (GBS) infection in both infants and adults prompted investigation of an effective vaccine against these organisms. Purified GBS type V polysaccharide was covalently linked to tetanus toxoid to form a type V polysaccharide-tetanus toxoid conjugate vaccine. The conjugate elicited type V polysaccharide-specific IgG antibodies in rabbits, while unconjugated type V polysaccharide did not. Conjugate-induced rabbit antibodies were opsonic in vitro and protected mice against challenge with type V GBS. Efficacy of the conjugate vaccine also was demonstrated in a maternal vaccination/neonatal challenge model in mice. A GBS type V polysaccharide-tetanus toxoid conjugate is an effective immunogen in animal models and may be a useful component for inclusion in a multivalent GBS vaccine for human use.
最近，V型菌株被确认为婴儿和成人B族链球菌（GBS）感染的常见病因，这促使人们对针对这些病原体的有效疫苗展开研究。纯化的GBS V型多糖与破伤风类毒素共价连接，形成V型多糖-破伤风类毒素结合疫苗。该结合疫苗在兔体内引发了V型多糖特异性IgG抗体，而未结合的V型多糖则没有。结合疫苗诱导产生的兔抗体在体外具有调理作用，并能保护小鼠免受V型GBS的攻击。结合疫苗的有效性在小鼠的母体免疫/新生儿攻击模型中也得到了证实。GBS V型多糖-破伤风类毒素结合疫苗在动物模型中是一种有效的免疫原，可能是用于人类的多价GBS疫苗的有用成分。
